SCHEMBL2655965

SCHEMBL2655965

COc1ccc(F)c(-c2c(F)ccc3c(N)c4c(nc23)CN(C2=CC=C2)C4=O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRG2 P18507 8/20 0.40
▸ GABRB3 P28472 8/20 0.40
▸ GABRA2 P47869 8/20 0.40
▸ EEF2K O00418 1/20 0.37
▸ TYMS P04818 1/20 0.32
▸ IDH2 P48735 1/20 0.32
▸ GRM2 Q14416 2/20 0.31
▸ PDE2A O00408 2/20 0.31
▸ PDE10A Q9Y233 2/20 0.31
▸ CTSD P07339 2/20 0.31
▸ BACE1 P56817 2/20 0.31
▸ ACHE P22303 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ PDE6D O43924 1/20 0.31
▸ PDE6A P16499 1/20 0.31
▸ PDE6G P18545 1/20 0.31
▸ PDE4A P27815 1/20 0.31
▸ PDE6B P35913 1/20 0.31
▸ PDE6C P51160 1/20 0.31
▸ PDE4B Q07343 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2659113 0.94 GABRG2 (0.47) GABRG2GABRB3GABRA2EEF2K
SCHEMBL2657000 0.92 GABRG2 (0.46) GABRG2GABRB3GABRA2EEF2KGRM2
SCHEMBL2660626 0.85 GABRG2 (0.37) GABRG2GABRB3GABRA2
SCHEMBL2658971 0.85 GABRG2 (0.39) GABRG2GABRB3GABRA2BACE1
SCHEMBL2657622 0.85 UGCG (0.35) GABRG2GABRB3GABRA2
SCHEMBL2660488 0.84 GABRG2 (0.48) GABRG2GABRB3GABRA2
SCHEMBL4916255 0.84 GABRG2 (0.33) GABRG2GABRB3GABRA2BACE1
SCHEMBL2656719 0.84 GABRG2 (0.39) GABRG2GABRB3GABRA2
SCHEMBL2658045 0.83 GABRG2 (0.34) GABRG2GABRB3GABRA2
SCHEMBL2658808 0.83 GABRG2 (0.44) GABRG2GABRB3GABRA2EEF2KTYMS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF GABRG2 592/4885GABRB3 332/4885GABRA2 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback